TACROLIMUS DOSAGE ADJUSTMENT ACCORDING TO CYP3A5 GENOTYPE IN KIDNEY TRANSPLANTATION: LONG-TERM RESULTS

被引：0
|
作者：
Lenain, R. [2 ]
Hamroun, A. [2 ]
Maanaoui, M. [2 ]
Van der Hauwaert, C. [3 ]
Broly, F. [1 ]
Labalette, M. [2 ]
Pottier, N. [2 ]
Cauffiez, C. [3 ]
Glowacki, F. [2 ]
机构：
[1] Ctr Biol Pathol Genet, Lille, France
[2] CHRU Lille, Lille, France
[3] EA4483, Lille, France
来源：
TRANSPLANT INTERNATIONAL | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
O55
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [1] Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype
    Pallet, N.
    Etienne, I.
    Buchler, M.
    Bailly, E.
    de Ligny, B. Hurault
    Choukroun, G.
    Colosio, C.
    Thierry, A.
    Vigneau, C.
    Moulin, B.
    Le Meur, Y.
    Heng, A. -E.
    Legendre, C.
    Beaune, P.
    Loriot, M. A.
    Thervet, E.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 (09) : 2670 - 2675
  • [2] Tacrolimus dose could be individualized according to CYP3A5 genotype
    [J]. Nature Clinical Practice Nephrology, 2007, 3 (7): : 358 - 358
  • [3] Tacrolimus Therapeutic Drug Monitoring in Stable Kidney Transplantation and Individuation of CYP3A5 Genotype
    Allegri, L.
    Baldan, F.
    Vallone, C.
    Tulissi, P.
    Gropuzzo, M.
    Canelles, M. F.
    Righi, E.
    Adani, G. L.
    Baccarani, U.
    Montanaro, D.
    Risaliti, A.
    Damante, G.
    Baraldo, M.
    [J]. TRANSPLANTATION PROCEEDINGS, 2019, 51 (09) : 2917 - 2920
  • [4] CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine
    Kreutz, R.
    Bolbrinker, J.
    van der Sman-de Beer, F.
    Boeschoten, E. W.
    Dekker, F. W.
    Kain, S.
    Martus, P.
    Sietmann, A.
    Friedrichs, F.
    Stoll, M.
    Offermann, G.
    Beige, J.
    [J]. PHARMACOGENOMICS JOURNAL, 2008, 8 (06): : 416 - 422
  • [5] CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine
    R Kreutz
    J Bolbrinker
    F van der Sman-de Beer
    E W Boeschoten
    F W Dekker
    S Kain
    P Martus
    A Sietmann
    F Friedrichs
    M Stoll
    G Offermann
    J Beige
    [J]. The Pharmacogenomics Journal, 2008, 8 : 416 - 422
  • [6] Personalized Tacrolimus Doses Determined by CYP3A5 Genotype for Induction and Maintenance Phases of Kidney Transplantation
    Vannaprasaht, Suda
    Reungjui, Sirirat
    Supanya, Darika
    Sirivongs, Dhavee
    Pongskul, Cholatip
    Avihingsanon, Yingyos
    Tassaneeyakul, Wichittra
    [J]. CLINICAL THERAPEUTICS, 2013, 35 (11) : 1762 - 1769
  • [7] CYP3A5 polymorphism in kidney transplantation: individualizing tacrolimus dosing
    Pasari, Amit S.
    Balwani, Manish R.
    Bawankule, Charulata
    Sejpal, Kapil
    Gurjar, Prasad
    Kashiv, Pranjal
    Dubey, Shubham
    Malde, Sunny
    Gupta, Sushrut
    Pawar, Twinkle
    [J]. TRANSPLANTATION, 2024, 108 (09) : 170 - 170
  • [8] TIME TO REACH TACROLIMUS THERAPEUTIC LEVELS DURING THE FIRST MONTH POST KIDNEY TRANSPLANTATION IN CHILDREN ACCORDING TO CYP3A5 GENOTYPE
    Alvarez-Elias, A.
    Garcia-Roca, P.
    Velasquez-Jones, L.
    Valverde-Rosas, S.
    Varela-Fascinetto, G.
    Medeiros, M.
    [J]. PEDIATRIC TRANSPLANTATION, 2015, 19 : 90 - 90
  • [9] THE ROLE OF CYP3A5 GENOTYPE AND TACROLIMUS MONITORING IN STABLE KIDNEY TRANSPLANTATIONS
    Baraldo, Massimo
    Adani, Gian Luigi
    Righi, Elda
    Tulissi, Patrizia
    Vallone, Clotilde
    Baccarani, Umberto
    Damante, Giuseppe
    Risaliti, Andrea
    Montanaro, Domenico
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [10] ASSOCIATION BETWEEN TACROLIMUS AND CYP3A5 GENOTYPE IN PEDIATRIC KIDNEY TRANSPLANT
    Alghamdi, A.
    Lazear, D.
    Varnell, C.
    Seay, S.
    Hooper, D.
    Darland, L.
    Mizuno, T.
    Ramsey, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S10 - S10
12345